A Big Month Ahead for the FDA and Bristol-Myers Squibb

It's been a few months since Bristol-Myers Squibb (NYSE: BMY) completed its $74 billion purchase of Celgene, but investors still aren't sure if a couple of key assets that spurred the transaction will ever generate sales.